Metrics to compare | PHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHARPeersSector | |
|---|---|---|---|---|
P/E Ratio | 36.2x | −1.5x | −0.2x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | 2.3x | 4.1x | 2.7x | |
Upside (Analyst Target) | 100.3% | 103.6% | 66.0% | |
Fair Value Upside | Unlock | 11.4% | 10.8% | Unlock |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.